NurExone Biologics has been named a finalist in Falling Walls Venture 2025, a global platform that showcases the world’s most promising science-based start-ups. With plans to move into clinical trials next year with an exosome therapy for spinal cord injuries, Diana Turner caught up Dr Lior Shaltiel, CEO and Director. DT: What are the unique […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
